Navigating through the changing treatment landscape of advanced prostate cancer

Professor Heather Payne is joined by Dr Luis Martinez-Piñeiro, Professor Woet Gianotten, Dr Álvaro Pinto and Professor Ander Bjartell at the 13th Prostate Cancer Debate in Madrid.

The discussion opens with a conversation around the definition of advanced prostate cancer and the importance of taking into consideration disease volume and risk when categorising patients.

The panel discuss hormone sensitive prostate cancer and the latest advancements in the treatment of these patients. Dr Pinto talks around the lack of reliable biomarkers meaning that clinical factors and patient preference play a significant role in treatment selection.

The increased awareness of patients with non-metastatic castration resistant prostate cancer (nmCRPC) is also discussed and the ways in which this patient group are identified and characterised. The panel feel that results from the PROSPER and SPARTEN trials have provided more treatment opportunities for these patients; with PFS2 data highlighting the importance of subsequent treatments and the need for standardisation of monitoring this patient group.

Professor Gianotten also discusses the interplay between cancer and sexual relationships and the difference between sex and sexuality highlighting the need for a holistic approach to cancer therapy.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.